Dysphagia and Its Impact on Quality of Life of Head and Neck Cancer Patients: Institution Based Cross sectional Study

Tseganesh Asefa Yifru
University of Gondar

Sezer Kisa
Oslo Metropolitan University: OsloMet - storbyuniversitetet

Negalegn Getahun Dinegde
Addis Ababa University

Niguse Tadele Atnafu (✉ niguse.tadele@aau.edu.et)
Addis Ababa University College of Health Sciences  https://orcid.org/0000-0002-3765-3617

Research note

Keywords: MDADI, Impaired swallowing, Quality of life, Head and neck cancer

DOI: https://doi.org/10.21203/rs.3.rs-117238/v1

License: ☛ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Objective:** Assessing swallowing function using symptom-specific questionnaires on head and neck cancer (HNC) patients and supporting impaired swallowing to improve quality of life (QoL) of patients is recommended in different studies. However, there is no data that shows the effect of dysphagia on quality of life of Ethiopian patients. Hence, this study assessed the effect of dysphagia on quality of life domains of the MD Anderson Dysphagia inventory (MDADI) among head and neck cancer patients.

**Results:** The study sample consisted of mostly male (53.90%), employed (70.6%), single (57.80%) and completed some level of formal education (66.60%) with mean age of 42.58 years (SD ± 14.08 years) and medical expense for about 69.6% of patients was covered by the government. Most of the patients were suffering from advanced stage HNC (59.80%) and squamous cell carcinoma (62.70%) and the most prevalent tumor location was nasal cavity/ nasopharyngeal carcinoma (40.20%). The mean MDADI composite score was 53.29 (SD± 15.85). Being female, low income, suffering from laryngeal/ hypo pharyngeal cancer, suffering from advanced tumor and those undergoing a single modality therapy were key determinants of poor QoL related to swallowing problems in HNC patients.

Introduction

Dysphagia is a frequent sequel of head and neck cancer (HNC) and its treatment [1]. Patients with HNC report significant difficulty in swallowing [2, 3] which exacerbates with treatment intensification[4] and has a profound impact on social and physical well-being [5, 6] such as difficulty in eating solid foods, choking, cough up after swallow, strangling to swallow, taking extra time to swallow, altered social interactions, weight loss [4, 7, 8] and emotional consequences such as loss of enjoyment with eating, embarrassment, and dissatisfaction [9–12] throughout the course of a treatment and even after a completion of a therapy [13, 14].

Factors predictive of poor quality of life (QoL) due to dysphagia could be patient-related[15] such as smoking [16–18], alcohol abuse[16], age [16, 18, 19], lean mass [16], and gender [16, 19, 20]; tumor-related[15] such as advanced tumor stage [17, 21–24], location of HNC [25], such as patients with tongue [26], buccal[27], hypo pharyngeal [28] and laryngeal [29] tumors had worse dysphagia related QoL, type of treatment [15, 25, 30] in which higher level of dysphagia and lower QoL scores among patients who had radiotherapy [19], [31], [32], [29, 33] and surgery[19, 34, 35] and patients treated with concomitant chemotherapy have an exacerbated dysphagia and dietary problems[36]. Deterioration in swallowing function through time were also reported from before treatment to 3 months [3, 37, 38] and 6 months [17, 39] post treatment with some improvements at later times [17, 37, 38, 40].

Studies indicate the need for assessing QoL of cancer patients for a good understanding of the degree of improvement obtained with therapeutic procedures [2]. Despite this fact, no study in Ethiopia assessed this association and therefore, this study analyzed the association between dysphagia and QoL in patients undergoing treatment for HNC.
Methods

Patients and sampling strategy

The study population included both male and female adult head and neck cancer survivors, aged >=18 years, who had no evident cognitive impairment and eating disorder which were selected by a consecutive sampling method among patients who visited oncology clinics at Tikur Anbessa Specialized Hospital from February to April 2019.

The sample size was estimated using the population adjustment formula for single proportion estimation based on 95% confidence level, a precision of 5% and 50% expected prevalence since there was no prior study and a 10% non-response, yielding a total sample of 109 head and neck cancer patients.

Data collection tools

Document review

Patient cards were reviewed to identify patients diagnosed with head and neck cancer and to extract clinical characteristics as time elapsed since diagnosis, primary cancer site, cancer stage, type of carcinoma and type of treatment received.

Self-reported questionnaire

A self-reported questionnaire was also used to collect information on patients’ socio-demographic, such as age, sex, marital status, level of education, working condition, residence, income and modality of payment coverage for medical expenses.

A 20-item psychometrically validated, and reliable Amharic version MDADI questionnaire which is specifically developed to evaluate the impact of dysphagia in QoL in patients with HNC [41] was used. Each question has 5 possible responses (strongly agree, agree, no opinion, disagree, and strongly disagree), and it is scored from 1 to 5. The Global domain is shown separately. The composite mean score is obtained by adding the other 3 domains, calculating their mean and multiplying this by 20. The composite mean score ranged from 20 (extremely low functioning) to 100 (high functioning). Thus, a better day-to-day functioning and a better day-to-day QoL is represented by a higher MDADI score.

Statistical analysis

The overall reliability of this measure was determined to be very good (Cronbach’s coefficient alpha=0.924) and the subscale also had acceptable internal consistency (emotional, 0.79; functional, 0.71; physical, 0.89).

Questionnaire responses were used to construct categorical variables. Patients that were diagnosed with cancer within six months prior to data collection were defined as ‘newly diagnosed’, patients who were divorced, widowed, separated and never married are categorized as ‘Single’. Level of income was
determined based on their ability to cover their medical expenses and patients were categorized as ‘fee paying’ if they were economical able to pay their medical expenses and those patients who were involved in any income generating activity were categorized as employed. Furthermore, patients who took any combination of treatment modalities were categorized under ‘Multi-modality treatment’ and cancer stages III & IV were categorized under ‘Advanced’. Details of the categories of all variables could be found in “Results” section.

Descriptive statistics were used to analyze demographic and clinical characteristics of participants. In addition, the independent t-test (for two groups) and one-way ANOVA (for more than two groups) were used to compare means between the demographic and clinical features with 4 domains and the composite mean score of the MDADI and $P < 0.05$ was considered significant. Once it was determined that differences exist among the means, post hoc range tests and pairwise multiple comparisons were conducted to determine which means differ. All statistical tests were performed using version 24 SPSS statistical software.

**Results**

**Patient characteristics**

The study population consisted of 102 HNC patients (93.6% response rate), mostly males (53.90%), employed (70.6%), single (57.80%) and completed some level of formal education (66.60%) with mean age of 42.58 years (SD ± 14.08 years). Majority (69.6%) belonged to extremely low economic status and their medical expense was covered by the government. Most were suffering from advanced stage HNC (59.80%) and squamous cell carcinoma 64 (62.70%) and the prevalent tumor location was nasal cavity/ nasopharyngeal carcinoma (40.20%) and about 34.3% of patients were newly diagnosed. Combination of treatment modalities, including chemotherapy, radiation therapy, and surgery was the most prevalent type of treatment in which 55.90% of the patients had this all treatments (Supplementary file 1 & 2).

**MDADI scores**

The composite mean MDADI [28] score of 53.29 (15.85) and overall question score of 53.34 (16.96) was observed and the lowest scores were shown for the global score (44.51) and physical domain (49.4) (Supplementary file 3).

Tables 1 and 2 shows the mean differences in MDADI scores among different groups. Among socio-demographic characteristics, women had significantly lower composite mean ($p = 0.036$) and functional ($p = 0.030$) scale scores and, patients who were economically able to pay for their medical expenses had significantly higher composite mean scores in all MDADI domains except the global domain. Other socio-demographic variables which includes age, marital status, level of education, employment status, place of residence and smoking habit did not differ between each domain (Table 1).
| Variable                        | MDADI (Mean ± SD) |            |            |            |            |            |
|--------------------------------|--------------------|------------|------------|------------|------------|------------|
|                                |                    | All        | Composite  | Global     | Emotional  | Functional |
|                                |                    | questions  | mean       |            |            |            |
|                                |                    |            |            |            |            |            |
| Sex                            |                    |            |            |            |            |            |
| Male                           | 56.3 ± 18.5        | 56.3 ± 16.6| 47.6 ± 25.1| 58.7 ± 18.9| 61.2 ± 17.6| 52.6 ± 21.3|
| Female                         | 49.8 ± 14.4        | 49.7 ± 14.3| 40.8 ± 19.9| 54.3 ± 15.3| 53.6 ± 16.8| 45.7 ± 15.9|
| **P**                          | 0.054              | 0.036      | 0.139      | 0.204      | 0.030      | 0.069      |
| Age in years                   |                    |            |            |            |            |            |
| 18 to 43                       | 50.7 ± 16.0        | 51.6 ± 14.9| 41.8 ± 22.6| 53.7 ± 17.1| 55.3 ± 17.7| 47.1 ± 17.8|
| Above 43                       | 56.5 ± 17.7        | 55.3 ± 16.8| 47.8 ± 23.3| 60.2 ± 17.3| 60.5 ± 17.0| 52.3 ± 20.7|
| **P**                          | 0.086              | 0.241      | 0.189      | 0.060      | 0.140      | 0.169      |
| Marital status                 |                    |            |            |            |            |            |
| Living alone                   | 55.4 ± 16.8        | 54.7 ± 15.5| 47.8 ± 24.4| 58.9 ± 17.3| 59.3 ± 16.8| 51.5 ± 19.1|
| Living with partner            | 50.4 ± 16.9        | 51.4 ± 16.3| 40.0 ± 20.5| 53.6 ± 17.4| 55.5 ± 18.5| 46.6 ± 19.4|
| **P**                          | 0.141              | 0.301      | 0.091      | 0.130      | 0.292      | 0.210      |
| Level of education             |                    |            |            |            |            |            |
| No formal Education            | 52.7 ± 14.7        | 53.3 ± 13.6| 44.7 ± 20.3| 55.2 ± 15.6| 56.0 ± 15.0| 49.8 ± 16.8|
| Primary                        | 50.6 ± 14.8        | 50.4 ± 13.9| 39.2 ± 20.8| 53.9 ± 15.8| 53.2 ± 17.0| 48.0 ± 16.5|
| Secondary                      | 54.1 ± 22.5        | 52.9 ± 21.2| 50.0 ± 28.5| 57.2 ± 21.5| 60.7 ± 20.1| 48.1 ± 25.7|
| Higher                         | 56.2 ± 17.8        | 56.3 ± 16.5| 45.4 ± 24.4| 60.6 ± 18.3| 62.0 ± 18.8| 51.3 ± 20.5|
| **P**                          | 0.705              | 0.630      | 0.508      | 0.534      | 0.263      | 0.929      |
| Employment status              |                    |            |            |            |            |            |
| Employed a                     | 54.8 ± 17.6        | 54.4 ± 16.6| 46.9 ± 24.5| 58.0 ± 17.9| 59.3 ± 17.6| 50.8 ± 20.4|
| Variable                     | MDADI (Mean ± SD) |                  |                  |                  |                  |
|------------------------------|-------------------|------------------|------------------|------------------|------------------|
|                              | All questions     | Composite mean   | Global           | Emotional        | Functional       | Physical         |
| Unemployed                   | 49.9 ± 14.9       | 50.6 ± 13.7      | 38.7 ± 18.1      | 53.3 ± 15.9      | 53.9 ± 17.1      | 46.3 ± 16.1      |
|                              | P 0.187           | 0.263            | 0.098            | 0.219            | 0.157            | 0.283            |
| Place of residence           |                   |                  |                  |                  |                  |                  |
| Addis Ababa                  | 48.8 ± 17.1       | 49.1 ± 17.7      | 39.2 ± 22.9      | 52.9 ± 17.5      | 55.1 ± 19.1      | 43.8 ± 20.3      |
|                              | P 0.118           | 0.119            | 0.177            | 0.214            | 0.382            | 0.081            |
| Regional /rural              | 54.9 ± 16.7       | 54.7 ± 15.0      | 46.3 ± 22.9      | 57.9 ± 17.4      | 58.6 ± 17.0      | 51.4 ± 18.6      |
|                              | P 0.118           | 0.119            | 0.177            | 0.214            | 0.382            | 0.081            |
| Level of income/ medical expenses coverage |                   |                  |                  |                  |                  |                  |
| Fee paying                   | 60.7 ± 19.7       | 58.9 ± 19.8      | 50.9 ± 25.7      | 64.3 ± 17.9      | 65.7 ± 19.3      | 56.8 ± 24.2      |
| Covered by government        | 50.1 ± 14.6       | 50.8 ± 13.2      | 41.7 ± 21.3      | 53.3 ± 16.2      | 54.2 ± 15.6      | 46.2 ± 15.8      |
|                              | P 0.003*          | 0.018*           | 0.061            | 0.003*           | 0.002*           | 0.010*           |
| Smoking                      |                   |                  |                  |                  |                  |                  |
| Yes                          | 52.3 ± 15.4       | 52.4 ± 14.9      | 43.4 ± 22.2      | 56.4 ± 15.6      | 56.6 ± 16.6      | 47.9 ± 17.8      |
| No                           | 57.5 ± 22.3       | 56.8 ± 19.5      | 49.0 ± 26.3      | 57.5 ± 24.1      | 62.0 ± 21.0      | 55.6 ± 24.0      |
|                              | P 0.229           | 0.266            | 0.333            | 0.806            | 0.222            | 0.109            |

Notes: t test (for two groups comparison) and one-way ANOVA (for three and above group comparison) were employed, * significant at p-value less than 0.05.
Table 2
Mean Differences of MDADI Subscales according to Clinical and Treatment Variables of Participants

| Variable | MDADI (Mean ± SD) | All questions | Composite mean | Global | Emotional | Functional | Physical |
|----------|-------------------|---------------|----------------|--------|-----------|------------|----------|
| **Time since diagnosis** | | | | | | | |
| New | 52.1 ± 17.1 | 51.9 ± 15.4 | 44.6 ± 24.3 | 55.9 ± 16.9 | 56.5 ± 17.9 | 47.4 ± 19.0 |
| 6 to 12 months | 53.1 ± 16.2 | 46.7 ± 24.4 | 54.4 ± 18.9 | 55.8 ± 17.2 | 50.7 ± 18.9 |
| More than year ago | 52.9 ± 17.4 | 55.1 ± 16.3 | 41.9 ± 20.2 | 60.1 ± 16.2 | 61.3 ± 17.4 | 50.2 ± 20.3 |
| P | 0.729 | 0.333 | 0.707 | 0.389 | 0.389 | 0.749 |
| **Primary tumor site** | | | | | | | |
| Oral cavity/ Oropharyngeal | 57.4 ± 20.8 | 57.4 ± 18.4 | 52.0 ± 28.1 | 59.3 ± 20.9 | 60.7 ± 20.5 | 54.5 ± 22.8 |
| Nasal cavity/ Nasopharyngeal | 55.0 ± 16.4 | 54.7 ± 16.1 | 43.9 ± 21.1 | 59.0 ± 16.4 | 59.9 ± 16.9 | 50.8 ± 19.8 |
| Larynx/ Hypopharyngeal | 47.2 ± 11.5 | 47.5 ± 11.2 | 38.1 ± 18.2 | 50.9 ± 13.8 | 51.9 ± 14.1 | 42.7 ± 12.2 |
| P | 0.044* | 0.040* | 0.058* | 0.086 | 0.084 | 0.045* |
| **Tumor T stage** | | | | | | | |
| Initial | 57.5 ± 18.2 | 57.7 ± 15.8 | 50.7 ± 24.9 | 60.5 ± 18.4 | 61.8 ± 16.8 | 53.4 ± 20.8 |
| Advanced | 50.6 ± 15.6 | 50.3 ± 15.3 | 40.3 ± 20.8 | 54.0 ± 16.4 | 54.9 ± 17.6 | 46.8 ± 17.9 |
| P | 0.042* | 0.019* | 0.024* | 0.067 | 0.049* | 0.092 |
| **Type of carcinoma** | | | | | | | |
| Squamous cell | 53.0 ± 16.6 | 53.3 ± 15.8 | 44.4 ± 22.1 | 56.0 ± 17.8 | 57.2 ± 17.2 | 49.5 ± 18.8 |
| Variable               | MDADI (Mean ± SD) | All questions | Composite mean | Global    | Emotional | Functional | Physical |
|-----------------------|-------------------|---------------|----------------|----------|-----------|------------|----------|
|                       |                   |               |                |          |           |            |          |
| Adenocarcinoma        |                   | 55.6 ± 19.5   | 54.7 ± 17.4    | 48.7 ± 25.5 | 58.3 ± 18.9 | 60.2 ± 20.2 | 51.5 ± 22.0 |
| Other                 |                   | 51.3 ± 15.1   | 51.2 ± 14.4    | 38.7 ± 23.3 | 56.7 ± 13.9 | 56.0 ± 15.0 | 45.8 ± 17.2 |
| P                     |                   | 0.730         | 0.803          | 0.425     | 0.874     | 0.725      | 0.676    |
| Treatment modality    |                   |               |                |          |           |            |          |
| Single modality       |                   | 50.5 ± 14.7   | 50.1 ± 14.0    | 40.9 ± 20.7 | 55.4 ± 15.9 | 55.7 ± 16.9 | 45.2 ± 16.7 |
| Treatment             |                   |               |                |          |           |            |          |
| Multi-modality        |                   | 55.5 ± 18.3   | 55.8 ± 16.9    | 47.2 ± 24.5 | 57.5 ± 18.6 | 59.2 ± 17.9 | 52.6 ± 20.6 |
| treatment            |                   |               |                |          |           |            |          |
| P                     |                   | 0.148         | 0.072          | 0.170     | 0.555     | 0.328      | 0.054    |

**Notes:** t-test (for two groups comparison) and one-way ANOVA (for three and above group comparison) were employed, * significant at p-value less than 0.05.

Regards to clinical features, statistically significant mean differences were observed between different primary tumor sites in all domains except the emotional and functional domains. In addition, patients with initial tumor stages (TI and II) had better scores in total questions \((p = 0.042)\), composite mean score \((p = 0.019)\), global \((p = 0.024)\) and functional \((p = 0.049)\) domains while worse scores in physical domain \((p = 0.054)\) was observed among patients who were undergoing single modality treatment. Time since diagnosis and type of carcinoma did not differ between each domain (Table 2).

Compared with patients with oral cavity/ oropharyngeal cancer, those patients with laryngeal/ hypopharyngeal cancer had significantly lower score in total questions \((p = 0.048)\), composite mean score \((p = 0.039)\), global \((p = 0.047)\) and physical \((p = 0.042)\) domains (Table 3).
Table 3
Multiple comparisons (Tukey HSD) between primary tumor site

| Dependent Variable | Primary tumor site | Primary tumor site | Mean Difference | P  | 95% CI Lower | 95% CI Upper |
|--------------------|--------------------|--------------------|-----------------|----|-------------|-------------|
| Total questions    | Oral cavity        | Nasal cavity       | 2.3             | .830 | -7.2        | 11.8        |
|                    | Larynx             |                    | 10.2*           | .048 | 0.1         | 20.3        |
|                    | Nasal cavity       | Larynx             | 7.9             | .120 | -1.6        | 17.3        |
| Composite mean     | Oral cavity        | Nasal cavity       | 2.7             | .748 | -6.2        | 11.6        |
|                    | Larynx             |                    | 9.8*            | .039 | 0.4         | 19.3        |
|                    | Nasal cavity       | Larynx             | 7.1             | .135 | -1.7        | 15.9        |
| Global             | Oral cavity        | Nasal cavity       | 8.1             | .299 | -4.8        | 21.0        |
|                    | Larynx             |                    | 13.9*           | .047 | 0.2         | 27.7        |
|                    | Nasal cavity       | Larynx             | 5.8             | .525 | -7.0        | 18.6        |
| Physical           | Oral cavity        | Nasal cavity       | 3.7             | .701 | -7.1        | 14.4        |
|                    | Larynx             |                    | 11.8*           | .042 | 0.4         | 23.3        |
|                    | Nasal cavity       | Larynx             | 8.2             | .167 | -2.5        | 18.9        |

Notes: *: The mean difference is significant at the 0.05 level.

Discussion

Considering the hypothesis that the presence of dysphagia increases the chances that the patient diagnosed and treated for HNC will present a reduction in their QoL, this study detected a composite mean of 53.29 in the MDADI, reflecting a mean reduction in the QoL due to swallowing changes in majority of studied patients, that is, the majority of patients reported that their swallowing limits their daily activities.

The composite MDADI mean scores in this study was considerably lower than 63.36 reported in Brazil [42], 64.06 and 67 and reported in USA [1, 43] and 67.08 reported in Taiwan [27] indicating the severity of this problem in Ethiopia. The variation may be due to the fact that patients in Ethiopia lack access to early treatment and support since there is a single cancer center in the country that provide comprehensive cancer care.

Similar to previous studies that reported patient-related factors such as, gender [16, 19, 20] and financial burden [18, 44, 45], tumor-related factors such as advanced tumor stage[21–23], location of HNC [25–29] and type of treatment [15, 25, 30], this study also identified that female sex, low income (who can't cover
their medical expenses), suffering from laryngeal/hypopharyngeal cancer, suffering from advanced tumor are key determinants of poor QoL related to swallowing problems in HNC patients. These results have direct implications at improving the care of HNC patients by highlighting the need to incorporate swallowing function in the assessment and clinical management of patients.

In contrast, unlike previous studies that reported factors such as, age\([16, 18, 19]\), marital status \([46]\), and smoking \([16–18]\) and deterioration in swallowing function through time \([17, 37, 38]\), no associations were observed between age, smoking habit, marital status, time since diagnosis and type of carcinoma in this study.

Female cancer patients in this study experienced poor swallowing related QoL consistent with earlier studies\([16, 19, 20]\). Women were more emotionally distressed, frustrated, embarrassed and depressed due to the inability to enjoy mealtime \([20]\) compared with male counterparts.

In this study, low-income patients scored lower MDADI scores in most of the domains which is consistent with the previous studies that linked financial burden from cancer with poor QoL \([18, 44, 45]\).

Our results were consistent with prior studies that identified the negative impact of stage and location of cancer on swallowing related QoL. It is interesting to note that worse MDADI scores among patients with advanced tumor stages and that had laryngeal/hypopharyngeal tumors observed in prior studies \([17, 21–29]\) were consistent with the risk observed for poorer QoL scores in our population. Patients that had oral cavity/oropharyngeal tumor and at initial tumor stages had better MDADI scores compared to patients with laryngeal/hypopharyngeal and an advanced stage cancer emphasizing the need to rigorously address swallowing function in such cancer patients.

Unlike the finding of studies done in Spain, Brazil and USA, \([2, 23, 47, 48]\), those patients received a multi-modality treatment were found to have a better scores compared to those with single modality treatment. This difference might be related to the fact that those patients with advanced stage cancer were less likely to had surgery and radiotherapy and any form of combination therapy due to their condition. Therefore, future studies should separately address the effect of therapy on swallowing problems for patients with early and advanced stage HNC patients in Ethiopia. As the burden of swallowing problems in HNC patients was established, it is crucial to incorporate swallowing function in routine cancer therapy protocols to mitigate the effect of dysphagia on QoL.

**Limitations**

To our knowledge, this study was the first in Ethiopia that assessed the effect of dysphagia on QoL and identified associated factors for poor dysphagia related QoL in HNC patients and provided baseline data that are essential to evaluate the progress of swallowing function in HNC patients. However, some limitations of this study warrant caution in interpreting the results. Mainly, cross-sectional nature of this study does not allow drawing any causal inferences. However, owing to the dearth of literature in this area, our results could direct future studies by allowing hypothesis generation and providing useful
information to target vulnerable populations. As self-reporting was used to collect patient information, our study was prone to recall bias. Furthermore, our questionnaire tailored to account for cultural sensitivities of Ethiopian patients may not be suitable for wider adoption without further validation.

**Abbreviations**

ANOVA: Analysis of Variance  
ETB: Ethiopian Birr  
HNC: head and neck cancer  
MDADI: MD Anderson Dysphagia inventory  
QoL: Quality of Life, SD: Standard Deviations  
SPSS: Statistical Package for the Social Sciences  
USA: United States of America

**Declarations**

**Ethics approval and consent to participate**

A written informed consent was obtained from all the participants. The study received ethical approval from Institutional Review Board of College of Health Sciences, School of Nursing and Midwifery [8/19/SNM].

**Consent for publication**

Not applicable

**Availability of data and materials**

The datasets used in this study are available upon request.

**Competing interests**

The authors declare that they have no competing interests

**Funding**
This study was funded by Addis Ababa University, College of Health Sciences, School of Nursing and Midwifery, Department of Nursing.

Authors' contributions

TA SK NG NT were involved in the conception and design of this study. TA and NT designed the final model and performed the experiments. TA completed final data analysis and wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to acknowledge the support of Addis Ababa University by funding this study and patients who respond to our questions.

References

1. Gillespie MB, Brodsky MB, Day TA, Lee FS, Martin-Harris B. Swallowing-related quality of life after head and neck cancer treatment. The Laryngoscope. 2004;114(8):1362-7.

2. Garcia-Peris P, Paron L, Velasco C, De la Cuerda C, Camblor M, Bretón I, et al. Long-term prevalence of oropharyngeal dysphagia in head and neck cancer patients: impact on quality of life. Clinical Nutrition. 2007;26(6):710-7.

3. Silva BAMSd. Eventos traumáticos na infância estão associados com a ocorrência de desordens emocionais e variáveis clinicopatológicas em pacientes com câncer de cabeça e pescoço. 2017.

4. Ottosson S, Laurell G, Olsson C. The experience of food, eating and meals following radiotherapy for head and neck cancer: a qualitative study. Journal of clinical nursing. 2013;22(7-8):1034-43.

5. Ganzer H, Rothpletz-Puglia P, Byham-Gray L, Murphy BA, Touger-Decker R. The eating experience in long-term survivors of head and neck cancer: a mixed-methods study. Supportive Care in Cancer. 2015;23(11):3257-68.

6. Nund RL, Ward EC, Scarinci NA, Cartmill B, Kuipers P, Porceddu SV. Survivors' experiences of dysphagia-related services following head and neck cancer: Implications for clinical practice. International journal of language & communication disorders. 2014;49(3):354-63.

7. Patterson JM, McColl E, Wilson J, Carding P, Rapley T. Head and neck cancer patients' perceptions of swallowing following chemoradiotherapy. Supportive Care in Cancer. 2015;23(12):3531-8.

8. Penner JL, editor Psychosocial care of patients with head and neck cancer. Seminars in oncology nursing; 2009: Elsevier.

9. Erinoso O, Okoturo E, Gbotolorun O, Effiom O, Awolola N, Soyemi S, et al. Emerging trends in the epidemiological pattern of head and neck cancers in Lagos, Nigeria. Annals of medical and health sciences research. 2016;6(5):301-7.
10. Vesela J, Grebenova S. The Influence of Psychological and Social Aspect on the Eating Habits of Primary School Children. School and Health. 2010;21:271-84.

11. Ames JA, Karnell LH, Gupta AK, Coleman TC, Karnell MP, Van Daele DJ, et al. Outcomes after the use of gastrostomy tubes in patients whose head and neck cancer was managed with radiation therapy. Head & neck. 2011;33(5):638-44.

12. Nguyen NP, Frank C, Moltz CC, Vos P, Smith HJ, Karlsson U, et al. Impact of dysphagia on quality of life after treatment of head-and-neck cancer. International Journal of Radiation Oncology* Biology* Physics. 2005;61(3):772-8.

13. Semple CJ, Dunwoody L, George Kernohan W, McCaughan E, Sullivan K. Changes and challenges to patients’ lifestyle patterns following treatment for head and neck cancer. Journal of advanced nursing. 2008;63(1):85-93.

14. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? The lancet oncology. 2006;7(11):935-43.

15. Starmer H, Sanguineti G, Marur S, Gourin CG. Multidisciplinary head and neck cancer clinic and adherence with speech pathology. Laryngoscope. 2011;121(10):2131-5. Epub 2011/08/10. doi: 10.1002/lary.21746. PubMed PMID: 21826674.

16. Eisbruch A, Lyden T, Bradford CR, Dawson LA, Haxer MJ, Miller AE, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. International Journal of Radiation Oncology • Biology • Physics. 2002;53(1):23-8. doi: 10.1016/S0360-3016(02)02712-8.

17. Goepfert RP, Lewin JS, Barrow MP, Fuller CD, Lai SY, Song J, et al. Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. The Laryngoscope. 2017;127(4):842-8. doi: 10.1002/lary.26153.

18. Reeve BB, Cai J, Zhang H, Weissler MC, Wisniewski K, Gross H, et al. Factors that impact health-related quality of life over time for individuals with head and neck cancer. The Laryngoscope. 2016;126(12):2718-25.

19. Pierre CS, Dassonville O, Chamorey E, Poissonnet G, Riss J-C, Ettaiche M, et al. Long-term functional outcomes and quality of life after oncologic surgery and microvascular reconstruction in patients with oral or oropharyngeal cancer. Acta oto-laryngologica. 2014;134(10):1086-93.

20. SAN SW, AHMAD A, MAHadeVAN B. The Swallowing Ability and Psychosocial Domains of Patients with Dysphagia among Head and Neck Cancer Population. Jurnal Sains Kesihatan Malaysia (Malaysian Journal of Health Sciences). 2018;17(1).

21. Chen S-C, Huang B-S, Chung C-Y, Lin C-Y, Fan K-H, Chang JT-C, et al. Effects of a swallowing exercise education program on dysphagia-specific health-related quality of life in oral cavity cancer patients post-treatment: a randomized controlled trial. Supportive Care in Cancer. 2018:1-10.

22. Langendijk JA, Doornaert P, Rietveld DH, Verdonck-de Leeuw IM, Leemans CR, Slotman BJ. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer.
23. Pauloski BR, Rademaker AW, Logemann JA, Stein D, Beery Q, Newman L, et al. Pretreatment swallowing function in patients with head and neck cancer. Head & Neck: Journal for the Sciences and Specialties of the Head and Neck. 2000;22(5):474-82.

24. Robertson SM, Yeo JCL, Sabey L, Young D, MacKenzie K. Effects of tumor staging and treatment modality on functional outcome and quality of life after treatment for laryngeal cancer. Head & Neck. 2013;35(12):1759-63. doi: 10.1002/hed.23230.

25. Karvonen-Gutierrez CA, Ronis DL, Fowler KE, Terrell JE, Gruber SB, Duffy SA. Quality of Life Scores Predict Survival Among Patients With Head and Neck Cancer. Journal of Clinical Oncology. 2008;26(16):2754-60. doi: 10.1200/jco.2007.12.9510. PubMed PMID: 18509185.

26. Daugaard R, Kjaer T, Johansen C, Christiansen J, Andersen E, Nielsen AL, et al. Association between late effects assessed by physicians and quality of life reported by head-and-neck cancer survivors. Acta Oncologica. 2017;56(2):342-7.

27. Chen S-C, Huang B-S, Hung T-M, Chang Y-L, Lin C-Y, Chung C-Y, et al. Swallowing ability and its impact on dysphagia-specific health-related QOL in oral cavity cancer patients post-treatment. European Journal of Oncology Nursing. 2018;36:89-94.

28. Frowen J, Drosdowsky A, Perry A, Corry J. Long-term swallowing after chemoradiotherapy: Prospective study of functional and patient-reported changes over time. Head & neck. 2016;38(S1):E307-E15.

29. Langius JA, Doornaert P, Spreeuwenberg MD, Langendijk JA, Leemans CR, van Bokhorst-de van der Schueren MA. Radiotherapy on the neck nodes predicts severe weight loss in patients with early stage laryngeal cancer. Radiother Oncol. 2010;97(1):80-5. Epub 2010/03/13. doi: 10.1016/j.radonc.2010.02.017. PubMed PMID: 20223540.

30. Dirix P, Abbeel S, Vanstraelen B, Hermans R, Nuyts S. Dysphagia After Chemoradiotherapy for Head-and-Neck Squamous Cell Carcinoma: Dose×Effect Relationships for the Swallowing Structures. International Journal of Radiation Oncology • Biology • Physics. 2009;75(2):385-92. doi: 10.1016/j.ijrobp.2008.11.041.

31. Noori AGM, Al-Rawaq KJ, Al-Nuaimi DSA, Fattah MAN. Quality of Life during Head and Neck External Beam Radiotherapy. MEDICAL SCIENCE. 2019;23(95):125-9.

32. Bonzanini LIL, Soldera EB, Schulz RE, Ortigara GB, Antoniazi RP, Ardenghi TM, et al. Quality of Life in Irradiated Head and Neck Cancer Patients: A Preliminary Study. Oral surgery, oral medicine, oral pathology and oral radiology. 2018;126(3):e173.

33. Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 2012;103(1):69-75. Epub 2012/03/09. doi: 10.1016/j.radonc.2012.01.002. PubMed PMID: 22398313.
34. Gaziano JE. Evaluation and Management of Oropharyngeal Dysphagia in Head and Neck Cancer. Cancer Control. 2002;9(5):400-9. doi: 10.1177/107327480200900505. PubMed PMID: 12410179.

35. Logemann JA, Larsen K. Oropharyngeal dysphagia: pathophysiology and diagnosis for the anniversary issue of Diseases of the Esophagus. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2012;25(4):299-304. Epub 2011/05/21. doi: 10.1111/j.1442-2050.2011.01210.x. PubMed PMID: 21595782.

36. Maurer J, Hipp M, Schäfer C, Kölbl O. Dysphagia. Strahlentherapie und Onkologie. 2011;187(11):744-9.

37. Khan MK, Patterson J, Owen S, Rees S, Gamberini L, Paleri V, et al. Comparing the Performance Status Scale and MD Anderson Dysphagia Inventory as swallowing outcome measures in head and neck cancer: a prospective cohort study. Clinical Otolaryngology. 2015;40(4):321-6. doi: 10.1111/coa.12369.

38. Wilson JA, Carding PN, Patterson JM. Dysphagia after Nonsurgical Head and Neck Cancer Treatment:Patients’ Perspectives. Otolaryngology–Head and Neck Surgery. 2011;145(5):767-71. doi: 10.1177/0194599811414506. PubMed PMID: 21746839.

39. Molassiotis A, Rogers M. Symptom experience and regaining normality in the first year following a diagnosis of head and neck cancer: a qualitative longitudinal study. Palliative & supportive care. 2012;10(3):197-204.

40. Fung K, Lyden TH, Lee J, Urba SG, Worden F, Eisbruch A, et al. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys. 2005;63(5):1395-9. Epub 2005/08/10. doi: 10.1016/j.ijrobp.2005.05.004. PubMed PMID: 16087298.

41. Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the MD Anderson dysphagia inventory. Archives of Otolaryngology–Head & Neck Surgery. 2001;127(7):870-6.

42. Andrade MS, Goncalves AN, Guedes RL, Barcelos CB, Slobodticov LD, Lopes SA, et al. Correlation between swallowing-related quality of life and videofluoroscopy after head and neck cancer treatment. CoDAS. 2017;29(1):e20150175. Epub 2017/03/17. doi: 10.1590/2317-1782/20172015175. PubMed PMID: 28300950.

43. Hutcheson KA, Barrow MP, Lisec A, Barringer DA, Gries K, Lewin JS. What is a clinically relevant difference in MDADI scores between groups of head and neck cancer patients? The Laryngoscope. 2016;126(5):1108-13. doi: 10.1002/lary.25778.

44. Egestad H, Nieder C. Undesirable financial effects of head and neck cancer radiotherapy during the initial treatment period. International journal of circumpolar health. 2015;74(1):26686.

45. Baxi SS, Salz T, Xiao H, Atoria CL, Ho A, Smith-Marrone S, et al. Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. Cancers of the Head & Neck. 2016;1(1):4.
46. Llewellyn CD, Homey DJ, McGurk M, Weinman J, Herold J, Altman K, et al. Assessing the psychological predictors of benefit finding in patients with head and neck cancer. Psycho-Oncology. 2013;22(1):97-105.

47. Vartanian JG, Carvalho AL, Yueh B, Priante AVM, de Melo RL, Correia LM, et al. Long-term quality-of-life evaluation after head and neck cancer treatment in a developing country. Archives of Otolaryngology–Head & Neck Surgery. 2004;130(10):1209-13.

48. Lahtinen S, Koivunen P, Ala-Kokko T, Kaarela O, Laurila P, Liisanantti JH. Swallowing-related quality of life after free flap surgery due to cancer of the head and neck. European Archives of Oto-Rhino-Laryngology. 2018:1-6.